Core Concepts
Maintaining asthma control reduces severe outcomes post COVID-19.
Abstract
Abstract and Introduction
- Patients with asthma during COVID-19 raised concerns.
- 2021 GINA report: asthma patients not at increased risk.
- Study: 163 patients evaluated pre and post COVID-19.
- 22.7% had COVID-19, longer asthma history in uncontrolled group.
- Treatment per GINA guideline, more uncontrolled patients in Step 1 and 5.
- GINA step 5 patients had worsened asthma with COVID-19.
- Optimal asthma control reduces severe outcomes post COVID-19.
Conclusion
- Optimal asthma control reduces severe outcomes post COVID-19.
- Communication with specialists via phone comforting for patients.
Stats
22.7% of asthma patients had COVID-19.
Asthma history longer in uncontrolled group.
18.4% of patients on allergen immunotherapy treatment.
Worsened asthma in GINA step 5 patients with COVID-19.
Severe COVID-19 led to severe asthma impairment.
Quotes
"Maintaining optimal asthma control should reduce risk of severe outcomes after COVID-19 disease."
"Communication via phone with specialists was comforting for patients."